| VEXMX | VNVAX | VEXMX / VNVAX | |
| Total Expense Ratio | 0.19 | 1.15 | 17% |
| Annual Report Gross Expense Ratio | 0.19 | 1.26 | 15% |
| Fund Existence | 38 years | 17 years | - |
| Gain YTD | 12.542 | -21.842 | -57% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 3000 | 2500 | 120% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 83.4B | 160M | 52,125% |
| Annual Yield % from dividends | 0.96 | 0.07 | 1,385% |
| Returns for 1 year | 9.81 | -23.59 | -42% |
| Returns for 3 years | 63.20 | -4.39 | -1,440% |
| Returns for 5 years | 29.01 | -12.19 | -238% |
| Returns for 10 years | 158.71 | -6.88 | -2,307% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| UBPSX | 20.59 | 0.16 | +0.78% |
| ProFunds UltraLatin America Svc | |||
| TRZKX | 75.91 | 0.12 | +0.16% |
| T. Rowe Price International Discovery Z | |||
| ISIIX | 14.09 | 0.01 | +0.07% |
| Voya International Index Port S2 | |||
| BUIDX | 35.08 | -0.05 | -0.14% |
| Buffalo Growth & Income Inst | |||
| ETCHX | 45.92 | -0.35 | -0.76% |
| Eventide Healthcare & Life Sciences C | |||